| Sagong, Min |
PROUD, NCT05666804: Study Assessing the Efficacy and Safety of a Personalized Monotherapy Regimen of Brolucizumab in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy |
|
|
| Recruiting | 3 | 160 | RoW | Brolucizumab 6mg, Beovu | Novartis Pharmaceuticals | Macular Polypoidal Choroidal Vasculopathy (PCV) | 09/25 | 09/25 | | |
EB-203-201, NCT06487039: Trial to Evaluate the Safety and Efficacy of EB-203 in Patients With Neovascular Age-related Macular Degeneration |
|
|
| Recruiting | 2 | 50 | RoW | EB-203 | EyebioKorea, Inc. | Neovascular Age-related Macular Degeneration (nAMD) | 08/25 | 01/26 | | |
NCT06116916: Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema |
|
|
| Recruiting | 2 | 150 | Japan, US, RoW | KHK4951, Aflibercept Injection | Kyowa Kirin Co., Ltd. | Diabetic Macular Edema (DME) | 11/25 | 12/25 | | |
NCT06116890: Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration |
|
|
| Recruiting | 2 | 180 | Japan, US, RoW | KHK4951, Aflibercept Injection | Kyowa Kirin Co., Ltd. | Neovascular Age-Related Macular Degeneration (nAMD) | 11/25 | 12/25 | | |
PMC403-A01, NCT05953012: Study to Assess Safety and Tolerability of PMC-403 in Subjects With Neovascular Age-related Macular Degeneration |
|
|
| Recruiting | 1 | 36 | RoW | PMC-403, Monotherapy | PharmAbcine, C&R Research, Inc. | Neovascular Age-related Macular Degeneration | 05/24 | 10/25 | | |
| Park, Jung Tak |
NCT06493799: In Patients With Chronic Liver Diseases(Alcoholic Liver Disease and Non-Alcoholic Fatty Liver Disease), LAENNEC(Human Placenta Hydrolysate) is to Evaluate the Efficacy and Safety of Intravenous Drop |
|
|
| Not yet recruiting | 3 | 226 | NA | LAENNEC (Human Placenta Hydrolysate) IV, LAENNEC (Human Placenta Hydrolysate) SC | Green Cross Wellbeing | Chronic Liver Disease | 12/25 | 12/25 | | |
NCT05532124: Part A: In Patients With Chronic Liver Diseases, LAENNEC (Human Placenta Hydrolysate) is to Assess Safety and Tolerability After the Doses of Doses. Part B: Part A, it is to Determine the Optimal Dose by Evaluating Two Capacity and Placebo Groups. |
|
|
| Recruiting | 2 | 49 | RoW | LAENNEC (Human Placenta Hydrolysate), normal saline | Green Cross Wellbeing | Chronic Liver Disease | 03/23 | 06/23 | | |
| Woo, SeJoon |
PROUD, NCT05666804: Study Assessing the Efficacy and Safety of a Personalized Monotherapy Regimen of Brolucizumab in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy |
|
|
| Recruiting | 3 | 160 | RoW | Brolucizumab 6mg, Beovu | Novartis Pharmaceuticals | Macular Polypoidal Choroidal Vasculopathy (PCV) | 09/25 | 09/25 | | |
PMC403-A01, NCT05953012: Study to Assess Safety and Tolerability of PMC-403 in Subjects With Neovascular Age-related Macular Degeneration |
|
|
| Recruiting | 1 | 36 | RoW | PMC-403, Monotherapy | PharmAbcine, C&R Research, Inc. | Neovascular Age-related Macular Degeneration | 05/24 | 10/25 | | |
